Active Projects

Current projects completed or being executed by the Biomarkers Consortium include:


Projects Launched/Completed to Date [11]
Project Name/Committee Objective Launch Date
FDG-PET Lung and Lymphoma Projects (2 projects—Cancer Steering Committee [CSC]) Build the case for FDA incorporation of FDG-PET into outcome measures for lung cancer and lymphoma March 2007 (lung);
May 2007 (lymphoma)
ISPY-2 TRIAL (CSC) A personalized medicine trial that promises to accelerate the pace of identifying effective novel agents for breast cancer; patients will be classified according to biomarker profiles and randomized to control therapy for up to 12 agents March 2010
Carotid MRI Reproducibility Project (MDSC) Establish a standardized carotid MRI protocol and determine the impact of site/platform on reproducibility September 2008
Sarcopenia Consensus Summit (MDSC) Generate a definition of sarcopenia (age-related decrease in skeletal muscle mass) to provide specific guidelines for diagnosis/enable regulatory decisions July 2009
Identification and Validation of Markers that Predict Long-Term Beta Cell Function and Mass (MDSC) Methodologic studies of the Meal Tolerance and the Maximum Stimulation Tests to validate and extend published data, as a pre-requisite for a clinical trial of diabetes progression January 2011
Alzheimer’s Disease (AD) Targeted Plasma Proteomics Project (Neuroscience Steering Committee [NSC]) Qualify a multiplexed panel of known AD plasma-based biomarkers using plasma samples from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) December 2008
PET Radioligand Project (NSC) Develop improved, more sensitive radioligands with higher binding to the peripheral benzodiazepine receptor January 2009
AD/Mild Cognitive Impairment (MCI) Placebo Data Analysis Project (NSC) Combine placebo data from large industry clinical trials and analyze them to provide better measures of cognition and disease progression February 2010
AD Targeted Cerebrospinal Fluid (CSF) Proteomics Project (NSC) Qualify a multiplexed panel of known AD CSF-based biomarkers; examine Beta-Site APP Cleaving Enzyme (BACE) levels in CSF; and qualify a mass spectroscopy panel using CSF samples from ADNI June 2010